Novartis AG ADR (NVS)vsRevelation Biosciences Inc (REVB)
NVS
Novartis AG ADR
$146.88
-0.80%
HEALTHCARE · Cap: $271.25B
REVB
Revelation Biosciences Inc
$0.81
-5.27%
HEALTHCARE · Cap: $3.71M
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 22.5% profit margin vs 0.0%. REVB trades at a lower P/E of 0.0x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
REVB
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.7%
Fair Value
$93.40
Current Price
$146.88
$53.48 premium
Intrinsic value data unavailable for REVB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : REVB
The strongest argument for REVB centers on P/E Ratio, Price/Book, Debt/Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : REVB
The primary concerns for REVB are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 31/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Revelation Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of immunological diagnostics and therapeutics for the prevention and treatment of disease. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?